摘要
目的评价组织间植入碘-125(^(125)I)粒子治疗恶性肿瘤的临床价值。方法 27例恶性肿瘤患者,其中肝癌肺转移10例、原发性肝癌4例、肝癌椎体转移3例、结肠癌肺转移3例、胰腺癌3例、肺癌2例、肝癌腹壁转移1例、十二指肠乳头癌术后局部复发并不全肠梗阻1例,在CT导向下植入^(125)I粒子,利用治疗计划系统(TPS)确定植入粒子的数量及位置,术后2个月复查CT评估疗效。结果 27例中,完全缓解(CR)5例,部分缓解(PR)13例,稳定(SD)7例,进展(PD)2例,总有效率66.7%,无严重并发症发生。结论碘-125粒子植入治疗恶性肿瘤安全、微创,近期疗效肯定。
Objective To evaluate the clinical value of125I seed interstitial brachytherapy intreatment of malignant tumor. Methods Twenty-seven patients with malignant tumor,including10 cases oflung metastasis of hepatoma,4 primary hepatoma,3 vertebras metastasis of hepatoma,3 lung metastasis of colon cancer,3 pancreatic cancer,2 lung cancer,1 abdominalwall metastasis ofhepatomaand 1 postoperative local recurrence of duodenal papillary carcinoma withpartial ileus,underwent CT-guided125I seeds implantation,and the number and site of seeds were determined bytreatment planning system（ TPS）. The clinical efficacy of implantation was evaluated by means of CT scanningtwo months later. Results Among 27 cases of patients,5 cases achieved complete remission（ CR）,13 partial remission（ PR）,7 withstable disease（ SD） and 2 progressive disease（ PD）,with total response rate 66. 7%. There was no severe complication occurred. Conclusion It is safe and minimally invasive for125I seed interstitial brachytherapy in treatment of malignant tumor with definite short-termefficacy.
出处
《安徽医学》
2016年第2期190-192,共3页
Anhui Medical Journal
